Drug design, development and therapy
Cure8 research brief
Why This Matters
People with IBD on biologic therapies may benefit from accurate drug-level testing to guide treatment decisions.
A validated multiplex LC‑MS/MS assay could enable simultaneous measurement of multiple therapeutic monoclonal antibodies, potentially improving efficiency for therapeutic drug monitoring and pharmacokinetic studies.
Who Should Pay Attention
Clinicians and laboratory specialists involved in TDM, researchers studying biologic pharmacokinetics in IBD, and patients on infliximab, vedolizumab, or ustekinumab interested in how drug levels are measured.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This paper describes a validated LC‑MS/MS laboratory method to measure three commonly used IBD monoclonal antibodies—infliximab, vedolizumab, and ustekinumab—simultaneously in human serum.
The authors used Protein G immunocapture, tryptic digestion, and MRM-based LC‑MS/MS with rituximab as an internal standard, then applied the assay to 37 residual patient samples.
The assay showed good analytical performance across clinically relevant ranges (linearity, precision, accuracy, selectivity, stability) and revealed substantial inter-patient variability in drug concentrations in the small exploratory sample set.
The study notes limitations: missing clinical covariates (weight, dosing history) and the need for cross-platform comparison, incurred sample reanalysis, and larger external validation before routine clinical TDM use.
Practical takeaway: this work presents a promising multiplex laboratory technique that could support pharmacokinetic research and future TDM workflows, but it is not yet established as a ready-for-clinic test.
Keep In Mind
Structured content depth: abstract — summaries and performance metrics are grounded in the article abstract. The study used 37 residual samples; authors highlight the need for cross-platform and external validation before clinical implementation.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationDrug design, development and therapy
AuthorsZhang Y, Wang N, Zheng W +5 more
Study typeIm, journal article
Indexed viaEurope PMC
Source typeResearch paper
PublishedSep 28, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Switching Between Anti-TNFs and Other Biologic Drugs in Paediatric Inflammatory Bowel Disease: A Narrative Review and Practical Clinical Guide.
Switching biologics is a frequent and consequential decision in children with IBD; using TDM and a mechanism‑based approach can help choose whether to optimize, switch within class, or change drug class.
DYNAMIC-UC: Early qFIT and Calprotectin Change Predicting Relapse in Biologic-Naive Ulcerative Colitis
Early changes in stool tests (qFIT and fecal calprotectin) might help predict which biologic‑naive ulcerative colitis patients will relapse or need escalation to biologic/JAK therapy. If validated, such markers could...
Real-world data on clinical response to inflammatory bowel disease biological treatments in patients with concurrent primary sclerosing cholangitis: a case-control study.
This study suggests that people with PSC-IBD may respond differently to some biologic treatments: infliximab and vedolizumab had similar early effectiveness versus IBD alone, but ustekinumab showed a lower early response...